LMR Partners LLP Invests $5.04 Million in Envista Holdings Co. (NYSE:NVST)

LMR Partners LLP purchased a new position in Envista Holdings Co. (NYSE:NVST) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 261,127 shares of the company’s stock, valued at approximately $5,037,000. LMR Partners LLP owned about 0.15% of Envista at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Franklin Resources Inc. raised its stake in shares of Envista by 72.6% in the 4th quarter. Franklin Resources Inc. now owns 6,854,506 shares of the company’s stock valued at $132,223,000 after purchasing an additional 2,882,844 shares in the last quarter. Norges Bank acquired a new stake in Envista during the fourth quarter valued at approximately $38,052,000. Dimensional Fund Advisors LP lifted its holdings in Envista by 19.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 6,762,091 shares of the company’s stock worth $130,440,000 after buying an additional 1,089,923 shares during the last quarter. Deerfield Management Company L.P. Series C grew its position in shares of Envista by 4,949.9% in the 4th quarter. Deerfield Management Company L.P. Series C now owns 1,018,415 shares of the company’s stock worth $19,645,000 after acquiring an additional 998,248 shares in the last quarter. Finally, Pzena Investment Management LLC acquired a new stake in shares of Envista during the fourth quarter worth $16,979,000.

Envista Price Performance

Shares of NYSE NVST opened at $18.56 on Tuesday. The firm’s 50-day simple moving average is $16.49 and its 200 day simple moving average is $18.99. The stock has a market cap of $3.15 billion, a P/E ratio of -2.86, a P/E/G ratio of 1.27 and a beta of 0.97. The company has a quick ratio of 1.76, a current ratio of 2.04 and a debt-to-equity ratio of 0.44. Envista Holdings Co. has a fifty-two week low of $14.22 and a fifty-two week high of $23.00.

Envista (NYSE:NVST) last issued its quarterly earnings results on Thursday, May 1st. The company reported $0.24 earnings per share for the quarter, topping analysts’ consensus estimates of $0.20 by $0.04. The company had revenue of $616.90 million during the quarter, compared to analyst estimates of $608.17 million. Envista had a negative net margin of 44.56% and a positive return on equity of 3.86%. The business’s revenue for the quarter was down 1.1% compared to the same quarter last year. During the same period in the prior year, the business posted $0.26 EPS. Equities analysts expect that Envista Holdings Co. will post 1 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. Robert W. Baird set a $21.00 target price on shares of Envista in a report on Friday, May 2nd. Needham & Company LLC reissued a “hold” rating on shares of Envista in a report on Thursday, March 6th. Piper Sandler reduced their price objective on Envista from $18.00 to $17.00 and set a “neutral” rating for the company in a research report on Wednesday, April 30th. JPMorgan Chase & Co. dropped their target price on Envista from $20.00 to $19.00 and set a “neutral” rating on the stock in a research report on Thursday, March 6th. Finally, Morgan Stanley set a $16.00 price target on shares of Envista in a report on Tuesday, April 15th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Envista has an average rating of “Hold” and an average price target of $20.08.

Envista Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.